SecBot SecBot
SECBOTREPLAY Home › Report › KYMR

KYMR · Kymera Therapeutics presented new preclinical data for KT-579, its oral…

Kymera Therapeutics, Inc. · PRESS-RELEASE filed Jun 8, 2026 at 07:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jun 8, 2026 at 07:00 ET

Kymera Therapeutics presented new preclinical data for KT-579, its oral IRF5 degrader, at EULAR and FOCIS meetings, showing disease-modifying activity comparable or superior to approved therapies in multiple lupus models. The Phase 1 healthy volunteer trial is ongoing with data expected in 2H26. This is a positive pipeline update for a mid-stage biotech, but preclinical data alone does not guarantee clinical success.

  • KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models.
  • Data presented at EULAR (June 3-6, 2026) and FOCIS (June 9-12, 2026) meetings.
  • KT-579 Phase 1 healthy volunteer trial is ongoing; data expected in second half of 2026.
  • KT-579 is a first-in-class oral degrader of IRF5, a genetically validated transcription factor.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access